MGZ
Medizinisch Genetisches Zentrum

2025

Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative.
Henkel J, Laner A, Locher M, Wohlfrom T, Neitzel B, Becker K, Neuhann T, Abicht A, Steinke-Lange V, Klink B, Eichhorn B, Schmidt W, Berner D, Teubert A, Holtorf A, Heinrich S, Wildhardt G, Schulze M, von der Heyden L, Hörtnagel K, Steinberger D, Kleier S, Lorenz P, Glaubitz R, Biskup S, Holinski-Feder E.
https://pubmed.ncbi.nlm.nih.gov/39854808/

2023

Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.
Henkel J, Laner A, Locher M, Wohlfrom T, **Neitzel B**, Becker K, Neuhann T, Abicht A, Steinke-Lange V, Holinski-Feder E.
https://pubmed.ncbi.nlm.nih.gov/37188824/

2020

Analysis of 3297 individuals suggests that the pathogenic germline 5'-UTR variant BRCA1 c.-107A > T is not common in south-east Germany.
Laner A, Benet-Pages A, **Neitzel B**, Holinski-Feder E. *Fam Cancer*. 2020;19(3):211-213. doi:10.1007/s10689-020-00175-4

2014

A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, Camu W, **Neitzel B**, Onodera O, van Rheenen W, Pinto S, Weber M, Smith B, Proven M, Talbot K, Keagle P, Chesi A, Ratti A, van der Zee J, Alstermark H, Birve A, Calini D, Nordin A, Tradowsky DC, Just W, Daoud H, Angerbauer S, DeJesus-Hernandez M, Konno T, Lloyd-Jani A, de Carvalho M, Mouzat K, Landers JE, Veldink JH, Silani V, Gitler AD, Shaw CE, Rouleau GA, van den Berg LH, Van Broeckhoven C, Rademakers R, Andersen PM, Kubisch C. *J Med Genet*. 2014;51(6):419-424. doi:10.1136/jmedgenet-2014-102360

2012

A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy. Horvath R, Holinski-Feder E, Neeve VCM, Pyle A, Griffin H, Ashok D, Foley C, Hudson G, Rautenstrauss B, Nürnberg G, Nürnberg P, Kortler J, **Neitzel B**, Bässmann I, Rahman T, Keavney B, Loughlin J, Hambleton S, Schoser B, Lochmüller H, Santibanez-Koref M, Chinnery PF. *Mov Disord*. 2012;27(6):789-793. doi:10.1002/mds.24980

2011

Chorea-acanthocytosis genotype in the original critchley kentucky neuroacanthocytosis kindred. Velayos-Baeza A, Holinski-Feder E, **Neitzel B**, Bader B, Critchley EMR, Monaco AP, Danek A, Walker RH. *Arch Neurol*. 2011;68(10):1330-1333. doi:10.1001/archneurol.2011.239

2005

Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families. Grabowski M, Mueller-Koch Y, Grasbon-Frodl E, Koehler U, Keller G, Vogelsang H, Dietmaier W, Kopp R, Siebers U, Schmitt W, **Neitzel B**, Gruber M, Doerner C, Kerker B, Ruemmele P, Henke G, Holinski-Feder E. *Genet Test*. 2005;9(2):138-146. doi:10.1089/gte.2005.9.138

MGZ
Medizinisch Genetisches Zentrum

2003

Easy, accurate and reliable screening for SNPs by ion pair/reverse phase HPLC: simultaneous detection of factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T variants. Neitzel B, Matern C, Holinski-Feder E. *Clin Lab*. 2003;49(7-8):313-318.

FMR1 gene deletion/reversion: a pitfall of fragile X carrier testing. Gasteiger M, Grasbon-Frodl E, **Neitzel B**, Kooy F, Holinski-Feder E. *Genet Test*. 2003;7(4):303-308. doi:10.1089/109065703322783653